Moujalled, Diane http://orcid.org/0000-0002-6405-2788
Southon, Adam G.
Saleh, Eiman
Brinkmann, Kerstin http://orcid.org/0000-0002-9411-6674
Ke, Francine http://orcid.org/0000-0001-8416-7665
Iliopoulos, Melinda
Cross, Ryan S.
Jenkins, Misty R. http://orcid.org/0000-0001-6564-2715
Nhu, Duong
Wang, Zilu
Shi, Melissa X. http://orcid.org/0000-0003-1454-9566
Kluck, Ruth M. http://orcid.org/0000-0002-7101-1925
Lessene, Guillaume http://orcid.org/0000-0002-1193-8147
Grabow, Stephanie
Bush, Ashley I. http://orcid.org/0000-0001-8259-9069
Strasser, Andreas http://orcid.org/0000-0002-5020-4891
Funding for this research was provided by:
Leukemia and Lymphoma Society (7015-18, 7015-18)
Department of Health | National Health and Medical Research Council (GNT1113133)
Leukemia and Lymphoma Society
Article History
Received: 23 July 2021
Revised: 3 March 2022
Accepted: 4 March 2022
First Online: 24 March 2022
Competing interests
: DM, ES., KB, FK, MI, RSC, MRJ, DN, ZW, MXS, RMK, GL, SG and AS are or were employees of WEHI which receives royalties from AbbVie and Genentech from the sale of Venetoclax. GL and AS are collaborating with and have received funding from Servier for work on the development of MCL-1-specific BH3 mimetic drugs for cancer therapy. AIB is a shareholder in Alterity Ltd, Cogstate Ltd and Mesoblast Ltd. He is a paid consultant fee for, and has a profit share interest in Collaborative Medicinal Development Pty Ltd.